Physician profile
Edwin M Purvis
NPI 1164409710
$4,438.61
in general payments reported to CMS, 2019-2025
25 companies · $404 in 2025
The $404 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $620 · 2021: $713 · 2022: $945 · 2023: $558 · 2024: $654 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,617.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,450.47 | 2021-2025 | Symplicity G3, Onyx Frontier |
| Novartis Pharmaceuticals Corporation | $1,071.14 | 2019-2025 | |
| Abiomed | $502.63 | 2019-2021 | |
| Inari Medical, INC. | $309.02 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $193.69 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $166.45 | 2020-2022 | |
| Pfizer INC. | $141.38 | 2019-2025 | |
| Medtronic Vascular, INC. | $83.53 | 2019 | |
| Janssen Pharmaceuticals, INC | $73.52 | 2019-2021 | |
| Esperion Therapeutics, INC. | $42.48 | 2021 | |
| Astellas Pharma US INC | $42.18 | 2020-2021 | |
| Abbott Laboratories | $37.49 | 2021-2023 | Cardiomems |
| Terumo Medical Corporation | $37.08 | 2023 | Glidewire, Metacross Otw |
| Atricure, INC. | $35.96 | 2023 | |
| Merck Sharp & Dohme LLC | $35.27 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $34.87 | 2019-2024 | Evkeeza |
| W. L. Gore & Associates, INC. | $30.88 | 2024 | Gore Tag Conformable Thoracic Stent Graft |
| Silk Road Medical, INC. | $27.90 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $24.98 | 2021-2022 | |
| Amarin Pharma, INC. | $22.51 | 2020 | |
| Cvrx, INC. | $18.53 | 2024 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $17.32 | 2024 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $16.16 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.88 | 2021 | |
| Amgen INC. | $11.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Purvis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.